|
Apr 27
|
Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc
|
|
Apr 26
|
10 Cathie Wood Stocks Insiders are Selling
|
|
Apr 24
|
Natera (NTRA) Rose on Momentum in the Oncology Market
|
|
Apr 24
|
CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
|
|
Apr 22
|
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
|
|
Apr 18
|
Insider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
|
|
Apr 17
|
TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
|
|
Apr 12
|
Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)
|
|
Apr 11
|
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
|
|
Apr 9
|
11 Best Biotech ETFs To Buy
|
|
Apr 8
|
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
|
|
Apr 5
|
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
|
|
Apr 5
|
Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive?
|
|
Apr 5
|
Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)
|
|
Apr 1
|
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
|
|
Mar 21
|
11 Best Healthcare ETFs To Buy Now
|
|
Mar 20
|
Will Natera (NTRA) Continue to Deliver Solid Topline Growth?
|
|
Mar 18
|
Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain
|
|
Mar 18
|
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
|
|
Mar 14
|
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
|